Literature DB >> 29796999

This is a call to oncologists for action.

C Micó1, A Berrocal2, A Blasco2, C Caballero2, V Iranzo2, M Lobo2, C Camps2,3,4,5.   

Abstract

Cancer cases are growing in an exponential way, likewise the prices of new cancer drugs. Continuing in this way, in the near future, it will be impossible to provide optimum care for all cancer patients. Therefore, it is important to establish mechanisms that enable the National Health Systems to provide the best options of treatment, either through the elaboration of decision-binding frameworks or through other initiatives that guarantee the best quality care for all oncology patients to overcome, in the best possible way, this difficult illness. Here, we review current proposals that have been established by different cancer organizations worldwide, their similarities, their differences and whether they are helpful in a real clinical setting. Facing present reality and despite these organizations' huge efforts, these proposals are not being implemented at all and it does not seem feasible that they will in the short run. In the same way, we support and argue why oncologists should have a crucial and a preponderant role to establish the best way of guaranteeing an equal access to the latest oncology care.

Entities:  

Keywords:  ASCO score; CanCon Project; Cancer costs; Cancer value; Drug Abacus; ESMO score; Evidence blocks; Frameworks tools; Health costs; Health economics; OncoSim; Oncologists

Mesh:

Substances:

Year:  2018        PMID: 29796999     DOI: 10.1007/s12094-018-1887-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  28 in total

1.  What is value in health care?

Authors:  Michael E Porter
Journal:  N Engl J Med       Date:  2010-12-08       Impact factor: 91.245

2.  Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.

Authors:  Tito Fojo; Sham Mailankody; Andrew Lo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-12       Impact factor: 6.223

3.  Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.

Authors:  Daniel J Becker; Daniel Lin; Steve Lee; Benjamin P Levy; Danil V Makarov; Heather T Gold; Scott Sherman
Journal:  J Oncol Pract       Date:  2017-05-11       Impact factor: 3.840

Review 4.  Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.

Authors:  Deborah Schrag; Morgan Hanger
Journal:  J Clin Oncol       Date:  2007-01-10       Impact factor: 44.544

5.  Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

6.  Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.

Authors:  A Vivot; J Jacot; J-D Zeitoun; P Ravaud; P Crequit; R Porcher
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

7.  Price transparency for MRIs increased use of less costly providers and triggered provider competition.

Authors:  Sze-jung Wu; Gosia Sylwestrzak; Christiane Shah; Andrea DeVries
Journal:  Health Aff (Millwood)       Date:  2014-08       Impact factor: 6.301

8.  Patients' expectations about effects of chemotherapy for advanced cancer.

Authors:  Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Authors:  N I Cherny; U Dafni; J Bogaerts; N J Latino; G Pentheroudakis; J-Y Douillard; J Tabernero; C Zielinski; M J Piccart; E G E de Vries
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.